- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07863167
An Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer.
The study is being conducted to evaluate the efficacy, and safety of SHR-A2009 combined with other anti-tumor therapies for perioperative treatment of resectable non-small cell lung cancer in adults.
Studieöversikt
Status
Betingelser
Intervention / Behandling
- Läkemedel: adebrelimab + SHR-A2009
- Läkemedel: adebrelimab + SHR-A2009
- Läkemedel: adebrelimab + SHR-A2009
- Läkemedel: paclitaxel or pemetrexed combined with carboplatin +adebrelimab
- Läkemedel: adebrelimab
- Läkemedel: adebeliizumab + SHR-A2009
- Läkemedel: adebeliizumab + SHR-A2009
- Läkemedel: adebeliizumab + platinum-containing double chemotherapy
- Läkemedel: almonertinib combined with SHR-A2009
- Läkemedel: almonertinib combined with SHR-A2009
- Läkemedel: almonertinib
- Läkemedel: SHR-A2009 combined with almonertinib
- Läkemedel: almonertinib monotherapy
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
Kontakter och platser
Studiekontakt
- Namn: Yijing Chen
- Telefonnummer: 0518-82342973
- E-post: yijing.chen.yc510@hengrui.com
Studieorter
-
-
Guangdong
-
Guangzhou, Guangdong, Kina, 510080
- Guangdong Provincial People's Hospital
-
Huvudutredare:
- Yilong Wu
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- voluntarily participate in this clinical study, understand the research procedure and be able to sign the informed consent in writing ;
- At the time of signing the informed consent form, the age is 18-70 years old ( including both ends ), both men and women can.
- The ECOG score was 0 or 1.
- Pathologically confirmed NSCLC, assessed as resectable or previously resected (R0).
- Adequate bone marrow and organ function.
Exclusion Criteria:
- Participants who received systemic immunostimulatory therapy within 4 weeks prior to the first dose.
- Participants who received systemic immunosuppressive therapy within 2 weeks before the first dose.
- Participants with active, known or suspected autoimmune diseases.
- Other malignant tumors within 5 years before screening.
- Participants with a history of interstitial pneumonia or cannot exclude interstitial pneumonia; or there are other moderate to severe lung diseases that may affect respiratory function. Or received previous pneumonectomy surgery.
- Participants with severe cardiovascular and cerebrovascular diseases.
- There were clinically significant bleeding symptoms or obvious bleeding tendency within 1 month before the first administration.
- Arterial and venous thrombosis events occurred within 3 months before the first administration.
- HIV test positive.
- Participants with active hepatitis B or C.
1.Evidence of active tuberculosis infection within 1 year before the first administration.
12.Severe infection occurred within 4 weeks before the first administration. 13.History of severe allergic reactions to other monoclonal antibody / fusion protein drugs.
14. Allergy to any component of the treatment regimen. 15.Participants were known to have a history of psychotropic drug abuse, alcohol abuse or drug abuse.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: group A1-1adebrelimab + SHR-A2009
|
adebrelimab + SHR-A2009 adebrelimab + SHR-A2009 (longer-interval regimen arm) adebrelimab + SHR-A2009 (shorter-interval regimen arm) |
|
Aktiv komparator: group A1-2 paclitaxel or pemetrexed combined with carboplatin +adebrelimab
|
paclitaxel or pemetrexed combined with carboplatin +adebrelimab |
|
Experimentell: group1 A2-1adebrelimab + SHR-A2009 (longer-interval regimen arm)
|
adebrelimab + SHR-A2009 adebrelimab + SHR-A2009 (longer-interval regimen arm) adebrelimab + SHR-A2009 (shorter-interval regimen arm) |
|
Experimentell: group2 A2-2adebrelimab + SHR-A2009 (shorter-interval regimen arm)
|
adebrelimab + SHR-A2009 adebrelimab + SHR-A2009 (longer-interval regimen arm) adebrelimab + SHR-A2009 (shorter-interval regimen arm) |
|
Aktiv komparator: group A2-3 adebrelimab
|
adebrelimab |
|
Experimentell: group1 A3-1 adebeliizumab + SHR-A2009 (longer-interval regimen arm)
|
adebeliizumab + SHR-A2009 (longer-interval regimen arm) adebeliizumab + SHR-A2009 (shorter-interval regimen arm) |
|
Experimentell: group2 A3-2 adebeliizumab + SHR-A2009 (shorter-interval regimen arm)
|
adebeliizumab + SHR-A2009 (longer-interval regimen arm) adebeliizumab + SHR-A2009 (shorter-interval regimen arm) |
|
Aktiv komparator: group A3-3 adebeliizumab + platinum-containing double chemotherapy
|
adebeliizumab + platinum-containing double chemotherapy |
|
Experimentell: group B1-1 almonertinib combined with SHR-A2009 (longer-interval regimen arm)
|
almonertinib combined with SHR-A2009 (longer-interval regimen arm) almonertinib combined with SHR-A2009 (shorter-interval regimen arm) |
|
Experimentell: group B1-2 almonertinib combined with SHR-A2009 (shorter-interval regimen arm)
|
almonertinib combined with SHR-A2009 (longer-interval regimen arm) almonertinib combined with SHR-A2009 (shorter-interval regimen arm) |
|
Aktiv komparator: group B1-3 almonertinib
|
almonertinib |
|
Experimentell: group B2-1 SHR-A2009 combined with almonertinib
|
SHR-A2009 combined with almonertinib |
|
Aktiv komparator: group B2-2 almonertinib monotherapy
|
almonertinib monotherapy |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Part A1 : pCR rate;
Tidsram: about 24 months
|
about 24 months
|
|
Part A2 : 2-year DFS rate;
Tidsram: about 24 months
|
about 24 months
|
|
Part A3 : pCR rate and 18-month EFS rate;
Tidsram: about 18 months
|
about 18 months
|
|
Part B1 : 2-year DFS rate.
Tidsram: about 24 months
|
about 24 months
|
|
Part B2 : MPR rate.
Tidsram: about 24 months
|
about 24 months
|
Sekundära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
The incidence and grade of adverse events;
Tidsram: about 48 months
|
about 48 months
|
|
surgical complications;
Tidsram: about 24 months
|
about 24 months
|
|
EFS
Tidsram: about 24 months ;
|
about 24 months ;
|
|
ORR;
Tidsram: about 24 months
|
about 24 months
|
|
DFS and DFS rates;
Tidsram: about 24 months
|
about 24 months
|
|
OS ;
Tidsram: about 48 months
|
about 48 months
|
Samarbetspartners och utredare
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Neoplasmer efter plats
- Neoplasmer
- Luftvägssjukdomar
- Lungsjukdomar
- Neoplasmer i andningsvägarna
- Thoracic neoplasmer
- Lungneoplasmer
- Karcinom, bronkogent
- Bronkiella neoplasmer
- Karcinom, icke-småcellig lunga
- Organiska kemikalier
- Kolväten
- Cykloparaffiner
- Kolväten, alicyklisk
- Kolväten, cykliska
- Terpener
- Taxoids
- Cyklodekaner
- Gentare
- Paklitaxel
- aumolertinib
Andra studie-ID-nummer
- SHR-A2009-203
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .